Table of Contents
GxP project management in pharma manufacturing is the discipline of planning, sequencing, and documenting every validation activity from equipment qualification (IQ/OQ/PQ) and computer system validation (CSV) through process validation and regulatory submission with enough traceability to survive an FDA inspection at any point. The “x” in GxP covers the full compliance spectrum: GMP for manufacturing, GLP for laboratory, GCP for clinical, GDP for distribution. Each carries its own documentation requirements, but they all converge on the same principle: every system, process, and piece of equipment that touches product quality must be validated, and that validation must be demonstrably current.
For CTOs and quality leadership in pharma manufacturing, GxP project management isn’t about task lists. It’s about maintaining a documented chain of evidence from user requirement specifications through design qualification, IQ, OQ, PQ, and periodic review that proves every system performs as intended and every deviation was investigated. When you’re running 15 or 20 validation projects simultaneously across a manufacturing site, and each follows the GAMP 5 V-model lifecycle with its own protocol approvals, test executions, and deviation workflows, the coordination challenge isn’t conceptual. It’s operational.
The enforcement landscape is pushing compliance upstream
The FDA’s Center for Drug Evaluation and Research (CDER) issued 50% more warning letters in FY2025 than the prior year (The FDA Group, December 2025). More than a third cited GMP violations, not exotic regulatory edge cases, but foundational gaps in documentation, process control, and data integrity that suggest quality systems aren’t functioning as designed.
An analysis of 85 warning letters issued to drug manufacturers in 2025 found that quality system issues accounted for over 30% of all citations, with identity testing of components (21 CFR 211.84(d)(1)) appearing in 49 of 85 letters as the single most common violation (Pharmaceutical Online / The FDA Group, 2025). Data integrity failures appeared in 15% of warning letters, but the distribution was sharply uneven: 60% of Indian facility letters cited DI issues versus 10% for U.S. sites and 21% for Chinese facilities (Pharmaceutical Online, 2025).
Perhaps most telling: the FDA recommended third-party GMP consultation in 87% of the 2025 warning letters reviewed, a near-universal signal that these weren’t isolated procedural misses but systemic quality management breakdowns requiring external remediation (Pharmaceutical Online, 2025).
The agency has also intensified its focus on computerized systems. The FDA finalized its Computer Software Assurance (CSA) guidance in September 2025, formalizing a risk-based approach to system validation that replaces the documentation-heavy CSV model many organizations still use. The EU followed with a draft revision of GMP Annex 11 in 2025, strengthening requirements around cybersecurity, audit trails, and supplier oversight for computerized systems. Meanwhile, ISPE published its GAMP Guide for Artificial Intelligence in July 2025, extending validation frameworks to AI-enabled systems in GxP environments.
Where the industry is heading: risk-based validation, CSA, and digital quality systems
The shift from traditional CSV to CSA represents the most significant change in pharma validation methodology in over a decade. Under the old model, organizations generated enormous documentation volumes for every computerized system regardless of risk. Under CSA, validation effort scales to the system’s actual impact on product quality and patient safety. A GAMP 5 Category 3 infrastructure component requires far less documentation than a Category 5 custom-built MES controlling batch release.
This risk-based shift means validation project management itself becomes more complex, not less. When each system in your portfolio carries a different validation scope based on its risk classification, you need project tracking that can model variable milestone gates, different documentation requirements per system category, and deviation workflows that trace back to specific risk assessments. Spreadsheets and email chains, which the FDA has repeatedly flagged through 21 CFR Part 11 citations, can’t provide that level of traceability at scale.
The GAMP 5 V-model lifecycle remains the industry standard framework: user requirements (URS) and functional specifications on the left side map to PQ, OQ, and IQ testing on the right, with design specifications and design qualification bridging the two. Each phase requires protocol approval before execution, documented test results, deviation investigation, and formal phase-gate sign-off before the next phase begins. Across 15–20 concurrent validation projects on a single manufacturing site, that’s hundreds of interdependent milestones, approvals, and document deliverables.
How OnePlan and SharePoint fit pharma’s validation tracking needs
OnePlan is a strategic portfolio and work management platform built on Microsoft Cloud, recognized as a “Strong Performer” in the Forrester Wave for Strategic Portfolio Management, Q2 2024, with the highest possible scores in integration and roadmap criteria. Microsoft has named OnePlan a Partner of the Year for project portfolio management for five consecutive years. Enterprise clients include Johnson & Johnson, Organon, and BioMarin.
For pharma manufacturing, OnePlan’s value sits at the portfolio level where validation programs are planned and tracked. Three capabilities map directly to GxP project management needs. Milestone-gated workflows let teams define phase gates, URS approval, DQ sign-off, IQ/OQ/PQ protocol execution, validation report approval, with dependency enforcement that prevents downstream work from starting until the prior gate is formally closed. Resource demand planning surfaces capacity constraints across validation engineers, QA reviewers, and commissioning specialists before those constraints delay go-live timelines. And financial planning tracks validation project costs against capital budgets, giving operations leadership visibility into spending across concurrent qualification programs.
SharePoint provides the document management layer that GxP compliance demands. Version-controlled protocol libraries, approval workflows with electronic signatures, audit trail logging, and role-based access controls align with 21 CFR Part 11 requirements for electronic records. When paired with OnePlan’s project tracking, the combination gives manufacturing teams a single Microsoft ecosystem for both execution management and document control without introducing standalone systems that themselves require validation.
OnePlan integrates natively with Microsoft Teams, Power BI, Azure DevOps, and Project for the web, alongside Jira, Smartsheet, and monday.com. Its Sofia GPT capability uses Microsoft OpenAI for AI-assisted resource forecasting and scenario analysis.
How Advaiya helps pharma manufacturers implement compliance-ready project management
Advaiya works with organizations across manufacturing, energy, and infrastructure on project and portfolio management implementations within the Microsoft ecosystem. When Advaiya deployed a document management system for a marine offshore service provider in a regulated environment, the results reflected what pharma manufacturers need from validation document control: 99% read acknowledgment, 100% version control accuracy, and 90% document search efficiency through a custom SharePoint-based DMS with audit logs and admin dashboards.
For pharma manufacturers evaluating OnePlan and SharePoint, Advaiya brings enterprise architecture expertise, Microsoft integration depth, and implementation methodology that connects compliance process design to platform configuration — so the tool maps to how your quality, validation, and operations teams actually execute GxP projects.
Connect with Advaiya about pharma manufacturing compliance →
FAQs
CSV is the traditional documentation-heavy validation approach. CSA, formalized by the FDA in September 2025, is a risk-based framework where validation effort scales to the system's actual impact on product quality.
Yes its milestone-gated workflows support dependency enforcement that prevents downstream phases from starting until prior gates are formally signed off.
SharePoint provides version control, electronic signatures, audit trails, and role-based access. Meeting Part 11 also depends on proper configuration, SOPs, and validation of the SharePoint environment itself.
Its portfolio view shows all active validation projects with resource demand, milestone status, and financial tracking so operations leadership sees cross-project dependencies and capacity constraints in real time.
